Ng George K 4

4 · Kintara Therapeutics, Inc. · Filed Oct 22, 2024

Form 4

Period: 2024-10-18

Director

Transactions

Award
Options (Right to Buy)
2024-10-18+35,780→ 35,780 total
Exercise: $2.24From: 2024-10-18Exp: 2030-02-06→ Common Stock (35,780 underlying)
Award
Options (Right to Buy)
2024-10-18+13,553→ 13,553 total
Exercise: $3.69From: 2024-10-18Exp: 2033-01-16→ Common Stock (13,553 underlying)
Award
Options (Right to Buy)
2024-10-18+13,553→ 13,553 total
Exercise: $4.14From: 2024-10-18Exp: 2034-02-28→ Common Stock (13,553 underlying)

Footnotes (1)

[F1]Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

Documents

1 file